Cancer Supportive Care Drugs Market Size - By Drug Class (G-CSFs, ESAs, Anti-emetics, Bisphosphonates, Opioids, NSAIDs), Cancer type (Breast, Lung, Prostate, Colorectal, Melanoma), Distribution Channel (Hospital, Drug Store), Global Forecast (2023 – 2032)
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCancer Supportive Care Drugs Market Size - By Drug Class (G-CSFs, ESAs, Anti-emetics, Bisphosphonates, Opioids, NSAIDs), Cancer type (Breast, Lung, Prostate, Colorectal, Melanoma), Distribution Channel (Hospital, Drug Store), Global Forecast (2023 – 2032)
Cancer Supportive Care Drugs Market Size
Cancer Supportive Care Drugs Market size was estimated to be USD 14.4 billion in 2022 and is predicted to increase at a growth rate of 1.9% till 2032. Progress in cancer treatments like chemotherapy, radiation therapy, targeted therapy, and immunotherapy has elevated treatment effectiveness. Prioritizing the well-being of cancer patients has gained significant prominence in cancer care.
The rise in awareness and education, the aging demographic, the growing inclination towards personalized medicine, and the growing population of cancer survivors have collectively emphasized the management of long-term treatment-related effects.
Moreover, the increasing global incidence and prevalence of cancer contribute to a growing patient population that requires supportive care. According to American Cancer Society, Inc. over 1.9 million new cancer cases is expected to be diagnosed in the U.S. in 2023. As more individuals are diagnosed with cancer, the demand for effective supportive care drugs to manage treatment-related side effects also rises.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Cancer Supportive Care Drugs Market Size in 2022 | USD 14.4 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 1.9% |
| 2032 Value Projection | USD 17.3 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 121 |
| Tables, Charts & Figures | 218 |
| Segments covered | Drug Class, Cancer Type, Distribution Channel, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact Analysis
The COVID-19 pandemic had a significant impact on the healthcare industry, including the cancer supportive care drugs market. Throughout the pandemic, various healthcare systems faced challenges with cancer treatment due to financial reallocation, lockdowns, and concerns about virus transmission.
Furthermore, numerous clinical studies for cancer medications, including supportive care drugs, were halted or postponed during the pandemic to prioritize patient safety. This interruption had implications for the development and testing of new supportive care drugs.
Nonetheless, telemedicine and remote healthcare services gained prominence during the pandemic to ensure patient safety. While certain supportive care services could be delivered online, the absence of in-person care might have influenced the overall management of treatment-related symptoms.
Cancer Supportive Care Drugs Market Trends
As healthcare for cancer patients evolves, several important trends are shaping the field1. Personalized Medicine Treatment is increasingly tailored to each patient's unique needs, focusing on managing symptoms and improving their overall well-being. 2. Targeted Therapies New therapies are being developed to address specific side effects of cancer treatment, offering more precise and effective relief. 3. Digital Health Integration Mobile apps and telemedicine are becoming integral parts of supportive care, empowering patients with information and remote access to care. 4. Long-Term Care Healthcare providers are paying more attention to managing the lasting effects of treatment, ensuring patients have the best possible quality of life. 5. Combination Therapies Supportive care drugs are now often combined with cancer treatments to optimize effectiveness and minimize side effects. 6. Biologic Agents Monoclonal antibodies and other biologic agents are being developed to target specific pathways involved in treatment-related symptoms, providing new avenues for relief. These trends reflect a growing recognition that enhancing the overall quality of life for cancer patients is essential. By effectively managing symptoms and providing comprehensive supportive care, healthcare professionals aim to help patients live well during and after cancer treatment.
Cancer Supportive Care Drugs Market Analysis
Hey there! Let's talk about the different types of medicines used to make cancer treatment easier, called cancer supportive care drugs. There are several main groupsDrugs that boost white blood cells (G-CSFs)These drugs are like little helpers that make your body produce more white blood cells called neutrophils. Neutrophils are important for fighting off infections. Chemotherapy drugs can sometimes damage these cells, so these drugs help prevent that. Drugs that help red blood cells (ESAs)These drugs can help your body produce more red blood cells, which carry oxygen around your body. Drugs that stop nausea and vomiting (anti-emetics)These drugs can help manage the nausea and vomiting that can come with chemotherapy. Drugs that prevent bone loss (bisphosphonates)These drugs can help protect your bones from damage caused by certain cancer treatments. Pain relievers (opioids and NSAIDs)These drugs can help manage pain from cancer and cancer treatments. Other drugsThis group includes other types of supportive care drugs, such as those that treat diarrhea or constipation. As of 2022, drugs that boost white blood cells (G-CSFs) were the most commonly used group. Why? Because they play a vital role in preventing neutropenia, a condition where the body doesn't have enough of these cells. Neutropenia can increase the?? of infections, which can delay or even stop cancer treatment. So, by using G-CSFs, doctors can help patients get the most out of their chemotherapy treatment by reducing their risk of infections.
Imagine having cancer and dealing with the challenges it brings, like pain, nausea, or feeling worn out. Doctors have specific medicines to help with these side effects and improve your quality of life. These medicines are called cancer supportive care drugs. They break the market into different types of cancer, like breast cancer, lung cancer, and so on. Out of these, breast cancer takes a big slice of the market, at around 14%. Breast cancer treatment is often a mix of surgery, radiation, and targeted therapies. Each of these can cause different side effects. For example, surgery can leave you with pain, while chemo can make you feel sick or tired. Supportive care drugs are like a helping hand that eases these symptoms and makes your journey a little easier. In the United States, about 1 in 8 women will have breast cancer during their lives. That's a lot of women who can benefit from these medicines.
Based on distribution channel, the cancer supportive care drugs market is segmented as hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a dominant industry share of 58.9% in 2022 and is expected to grow at a CAGR of 2% by 2032. Hospital pharmacists have specialized knowledge in oncology and supportive care drugs. They collaborate with healthcare teams to ensure appropriate drug selection, dosing, and administration based on individual patient needs.
Asia Pacific cancer supportive care drugs market accounted for significant revenue in 2022 and is expected to reach USD 6.1 billion in 2032 with a CAGR of 2.3% from 2023-2032. The Asia Pacific region has witnessed a rising incidence of cancer, attributed to factors such as population growth, aging, changing lifestyles, and environmental factors. As cancer cases increase, so does the demand for supportive care drugs to manage treatment-related symptoms.
Moreover, many countries in the Asia Pacific are adopting Western-style cancer treatments, including chemotherapy and targeted therapies. These therapies often come with side effects that require effective supportive care interventions.
Cancer Supportive Care Drugs Market Share
Major industry players operating in the cancer supportive care drugs market include
- Amgen, Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Heron Therapeutics, Inc.
- Novartis AG
- GSK plc
- F. Hoffmann-La Roche Ltd.
- Helsinn Healthcare SA,
- Teva Pharmaceuticals Industries Ltd.,
- Fagron Group.
Cancer Supportive Care Drugs Market Industry News
- In June 2020, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved NYVEPRIA (pegfilgrastim-apgf), a biosimilar of Neulasta (pegfilgrastim). NYVEPRIA was developed to reduce the risk of infection, as shown by febrile neutropenia, in patients with non-myeloid malignancies taking myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
The cancer supportive care drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By drug class
- G-CSFs (Granulocyte-colony Stimulating Factors)
- ESAs (Erythropoiesis Stimulating Agents)
- Anti-emetics
- Bisphosphonates
- Opioids
- NSAIDs
- Other drugs
By cancer type
- Breast cancer
- Lung cancer
- Melanoma
- Prostate cancer
- Colorectal cancer
- Liver cancer
- Stomach cancer
- Other cancer types
By distribution channel
- Hospital pharmacies
- Drug stores and retail pharmacies
- Online pharmacies
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy